Abstract:Tuberculosis is now recognized as the most fatal infectious disease worldwide, eclipsing HIV in recent years. Drug-resistance tuberculosis continues to be a severe public crisis. The cure rate in persons with multidrug-resistant tuberculosis (MDR-TB) is unacceptably low, and the treatment of MDR-TB requires complex treatment regimens over a long period. There is a great opportunity in the field of tuberculosis as novel chemical entities with different mechanisms of action are particularly needed. The biosynthesis and transport pathways of mycolic acid represents a well proven and effective target for chemical intervention for TB. This article reviews the important inhibitors targeting to this pathway, as well as the recent research advances in the mechanism and pharmacokinetic properties etc.

Recent Advances in Antitubercular Compounds Targeting Mycolic Acid Biosynthesis and Transport